Eckert & Ziegler stock gains 1.82 percent from prior close

Published on 10/07/2026 at 14:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half adjusted EBIT fell 6.00 percent to EUR 33.30 million. Eckert & Ziegler stock stood at EUR 12.32 on October 7, 2026 after EUR 12.10.

Aquarell eines modernen Forschungscampus mit Glas- und Betongebäuden — Eckert & Ziegler DE0005659700 Medizintechnik: Aquarellgemälde eines modernen Forschungscampus in Berlin mit Glasfassaden und Bäumen, Illustration mit AI erstellt.

Eckert & Ziegler stock was trading at EUR 12.32 at Lang & Schwarz on October 7, 2026 at 2:17 p.m. CEST, up 1.82 percent versus the prior close of EUR 12.10. The latest operating picture remains mixed: first-half 2026 revenue was EUR 149.30 million, while adjusted EBIT fell 6.00 percent to EUR 33.30 million, according to Trading-Treff in its September 10, 2026 report.

Revenue barely changes in first half

The revenue result compares with EUR 148.80 million in the first half of 2025, making the year-over-year increase EUR 0.50 million. Adjusted EBIT declined from EUR 35.40 million, while net income rose 5.00 percent to EUR 22.40 million.

The mix matters for the stock. The figures show that stable group revenue did not translate into stable operating earnings, placing greater emphasis on the second-half product mix and delivery schedule.

Guidance remains at EUR 320 million

Management kept its 2026 outlook at EUR 320.00 million of revenue and EUR 80.00 million of adjusted EBIT, as reported by Trading-Treff on September 10, 2026. The guidance implies a substantial second-half contribution because first-half adjusted EBIT reached EUR 33.30 million against the full-year target of EUR 80.00 million.

The company operates in medical and isotope products, with applications in cancer treatment, industrial radiometry, and nuclear medicine. Its investor-relations page reports fiscal-year 2025 revenue of EUR 312.00 million and adjusted EBIT of EUR 77.70 million, providing historical context for the current outlook.

Analyst target stays above market price

Trading-Treff reported that Berenberg maintained a Buy rating on August 26, 2026 and cited a EUR 23.00 price target. That target is EUR 10.68 above the Lang & Schwarz price, so the analyst view centers on execution against the unchanged outlook rather than on the first-half revenue trend alone.

The next reporting date is November 12, 2026, with third-quarter 2026 listed as the reporting period by TradingView. That update should show whether the second-half improvement embedded in the guidance is becoming visible in revenue and adjusted EBIT.

Stock remains near its yearly low

The Lang & Schwarz quote of EUR 12.32 on October 7, 2026 was EUR 0.22 above the prior close of EUR 12.10. The primary listing is on Xetra, where the finance snapshot showed a market capitalization of EUR 769.10 million and a 52-week range of EUR 11.91 to EUR 17.73 on October 7, 2026.

For investors, the central comparison is operational: first-half revenue was EUR 149.30 million versus EUR 148.80 million a year earlier, while adjusted EBIT fell from EUR 35.40 million to EUR 33.30 million. The November report will put the unchanged EUR 320.00 million revenue and EUR 80.00 million adjusted EBIT goals against another completed reporting period. The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.